Stockreport

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025

Compugen Ltd. - Ordinary Shares  (CGEN) 
Last compugen ltd. - ordinary shares earnings: 2/20 07:05 am Check Earnings Report
US:NASDAQ Investor Relations: cgen.com/investors/overview
PDF Pooled analysis supports the rationale for the ongoing MAIA-ovarian trial evaluating COM701 as maintenance therapy in the earlier setti [Read more]